Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
// Ravyn M. Thompson 1 , Dominik Dytfeld 2 , Leticia Reyes 1 , Reeder M. Robinson 1 , Brittany Smith 1 , Yefim Manevich 1 , Andrzej Jakubowiak 3 , Mieczyslaw Komarnicki 2 , Anna Przybylowicz-Chalecka 2 , Tomasz Szczepaniak 2 , Amit K. Mitra 5 , Brian G. Van Ness 5 , Magdalena Luczak 4 , Nathan G. Dolloff 1, * 1 Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA 2 Karol Marcinkowski University of Medical Sciences, Poznan, Poland 3 University of Chicago, Chicago, IL, USA 4 Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland 5 University of Minnesota, Minneapolis, MN, USA * These authors contributed equally to this work Correspondence to: Nathan G. Dolloff, email: dolloffn@musc.edu Keywords: multiple myeloma, proteasome inhibitor, glutaminase, carfilzomib Received: December 08, 2016 Accepted: March 01, 2017 Published: March 16, 2017 ABSTRACT Curative responses in the treatment of multiple myeloma (MM) are limited by the emergence of therapeutic resistance. To address this problem, we set out to identify druggable mechanisms that convey resistance to proteasome inhibitors (PIs; e.g., bortezomib), which are cornerstone agents in the treatment of MM. In isogenic pairs of PI sensitive and resistant cells, we observed stark differences in cellular bioenergetics between the divergent phenotypes. PI resistant cells exhibited increased mitochondrial respiration driven by glutamine as the principle fuel source. To target glutamine-induced respiration in PI resistant cells, we utilized the glutaminase-1 inhibitor, CB-839. CB-839 inhibited mitochondrial respiration and was more cytotoxic in PI resistant cells as a single agent. Furthermore, we found that CB-839 synergistically enhanced the activity of multiple PIs with the most dramatic synergy being observed with carfilzomib (Crflz), which was confirmed in a panel of genetically diverse PI sensitive and resistant MM cells. Mechanistically, CB-839 enhanced Crflz-induced ER stress and apoptosis, characterized by a robust induction of ATF4 and CHOP and the activation of caspases. Our findings suggest that the acquisition of PI resistance involves adaptations in cellular bioenergetics, supporting the combination of CB-839 with Crflz for the treatment of refractory MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · cited 1×
“Disease response to treatment was assessed by International Myeloma Working Group (IMWG) criteria [52].”
MethodGlutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity
Weinberg, F., Hamanaka, R., Wheaton, W. W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G. M., Budinger, G. R. S., & Chandel, N. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003428107 · Cited by 1,742
Nutrition Needs of Mammalian Cells in Tissue Culture
Eagle, H. (1955) · Science · doi:10.1126/science.122.3168.501 · Cited by 1,619
Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells.
Reitzer, L. J., Wice, B. M., & Kennell, D. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30124-2 · Cited by 1,240
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer
Gross, M. I., Demo, S. D., Dennison, J. B., Chen, L., Chernov-Rogan, T., Goyal, B., Janes, J. R., Laidig, G. J., Lewis, E. R., Li, J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0870 · Cited by 1,068
Regulation of mammalian nucleotide metabolism and biosynthesis
Lane, A. N., & Fan, T. W.-M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv047 · Cited by 959
Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation
Wang, J.-B., Erickson, J. W., Fuji, R., Ramachandran, S., Gao, P., Dinavahi, R., Wilson, K. F., Ambrosio, A. L. B., Dias, S. M. G., Dang, C. V., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.009 · Cited by 821
Ristow, M., & Zarse, K. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.03.014 · Cited by 789
A two-way street: reciprocal regulation of metabolism and signalling
Wellen, K. E., & Thompson, C. B. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3305 · Cited by 528 · cited 1×
“For example, glutamine is used directly as a building block in the de novo synthesis of purine and pyrimidine nucleotides [44], and in the hexosamine biosynthesis pathway that produces uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) for support of protein glycosylation, folding and trafficking [45].”
Background
Cited by
Metabolism of Amino Acids in Cancer
Wei, Z., Liu, X., Cheng, C., Yu, W., & Yi, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.603837 · Cited by 429
Galan-Cobo, A., Sitthideatphaiboon, P., Qu, X., Poteete, A., Pisegna, M. A., Tong, P., Chen, P.-H., Boroughs, L. K., Rodriguez, M. L. M., Zhang, W., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3527 · Cited by 292
“selectively and irreversibly inhibit glutaminase and have been reported to have anti-proliferative effects in various tumor cell types (11-14,16-18,37,38).”
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Hoerner, C. R., Chen, V. J., & Fan, A. C. (2019) · Kidney Cancer · doi:10.3233/kca-180043 · Cited by 68
Inhibition of glutaminase elicits senolysis in therapy-induced senescent melanoma cells
Kim, J., Brunetti, B., Kumar, A., Mangla, A., Honda, K., & Yoshida, A. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07284-3 · Cited by 16
Metadata
- Authors
- Thompson, R. M., Dytfeld, D., Reyes, L., Robinson, R. M., Smith, B., Manevich, Y., Jakubowiak, A., Komarnicki, M., Przybylowicz-Chalecka, A., Szczepaniak, T., Mitra, A. K., Van Ness, B. G., Luczak, M., & Dolloff, N. G.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-05-30
- Volume
- 8
- Issue
- 22
- Pages
- 35863-35876
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2597387377
- Cited by
- 126
- References
- 15
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. https://app.cochat.ai/papers/10.18632/oncotarget.16262
- The paper
- Thompson, R. M., Dytfeld, D., Reyes, L., Robinson, R. M., Smith, B., Manevich, Y., Jakubowiak, A., Komarnicki, M., Przybylowicz-Chalecka, A., Szczepaniak, T., Mitra, A. K., Van Ness, B. G., Luczak, M., & Dolloff, N. G. (2017). Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget. https://doi.org/10.18632/oncotarget.16262
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.